Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant
Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant
Data support progressing with Phase 3 clinical development program
Lexington, Mass. – October 27, 2016 –– For U.S. Audiences Only – Shire plc (LSE: SHP, NASDAQ: SHPG) today presented data from a Phase 2 study evaluating maribavir (SHP620), an investigational antiviral agent studied in patients with cytomegalovirus (CMV) infection undergoing hematopoietic stem cell transplant or solid organ transplant who are resistant or refractory to (val) ganciclovir or foscarnet, drugs currently used to treat these infections. In the study, 67% of patients treated with varying doses of maribavir (400 to 1200 mg twice daily) for up to 24 weeks had no detectable levels of the virus in their blood plasma within six weeks of starting treatment. Dysgeusia (taste disturbance) was the most commonly-reported treatment-emergent adverse event (AE) in this study. Other treatment-emergent AEs ≥20% for all doses included nausea, vomiting, CMV infection, diarrhea, fatigue, and anemia.
These data were presented during an oral abstract session at Infectious Disease Week (IDWeek) 2016 in New Orleans, La.
"Cytomegalovirus infection that is resistant or refractory to standard therapy in transplant patients is associated with significant complications and high mortality," said Genovefa Papanicolaou, M.D., Infectious Diseases Specialist at Memorial Sloan Kettering Cancer Center, and one of the clinical trial investigators. “The Phase 2 findings support further research to confirm these results among patients who have limited options to combat the infection.”
Cytomegalovirus (CMV) is a common infection that is related to the viruses that cause chickenpox and herpes simplex. The virus stays in the body for life once a person is infected, but may stay dormant. It frequently occurs in patients undergoing transplant procedures whose immune system is compromised. While currently-available systemic anti-CMV agents are effective against the virus, their use is limited by complications, most notably bone marrow suppression which can be problematic in patients who have undergone a hematopoietic stem cell transplant, and impairment of kidney function. Emergence of resistance against commonly used drugs can also be a problem for this population and there is a need for treatments to treat CMV infection that does not respond or is resistant to these drugs.
Maribavir has shown activity against CMV strains resistant to other agents. The agent was originally being developed by ViroPharma, Incorporated, which Shire acquired in November 2013. The U.S. Food and Drug Administration (FDA) and the European Commission have granted Orphan Drug Designation to maribavir for treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients, and treatment of cytomegalovirus disease in patients with impaired cell mediated immunity, respectively.
Howard B. Mayer, M.D. Head of Global Clinical Development, Shire, said, “Shire has a strong commitment to continuing research for small and underserved patient populations. We are extremely encouraged by these Phase 2 results, and will be progressing forward with our Phase 3 research program to further evaluate this agent’s efficacy and safety in these patients.”
The Phase 2 study included 120 patients ages 12 or older with CMV infection (≥1,000 DNA copies/mL of blood plasma) resistant or refractory to (val)ganciclovir or foscarnet. Patients were randomized to one of three, twice-daily oral doses of maribavir – 400 mg, 800 mg, or 1,200 mg – for up to 24 weeks of treatment. The primary safety analysis focused on the incidence of treatment-emergent AEs. The primary efficacy endpoint was the proportion of patients with confirmed undetectable plasma CMV DNA within six weeks of treatment.
Overall, 67% (80/120) of patients met the primary efficacy endpoint (95% CI: 57, 75). The results by dosage were: 70% for 400 mg twice daily (95% CI: 53, 83), 63% for 800 mg twice daily (95% CI: 46, 77), and 67% for 1,200 mg twice daily (95% CI: 51, 81). The infection recurred in 30 patients, including 7, 11, and 12 patients in the 400 mg, 800 mg, and 1,200 mg groups, respectively.
Dysgeusia was the most common AE, occurring in 65% of all patients, including 60%, 63%, and 73% of patients in the 400 mg, 800 mg, and 1,200 mg groups, respectively. Other treatment-emergent AEs ≥20% for all doses included nausea, vomiting, CMV infection, diarrhea, fatigue, and anemia. Immunosuppressant drug level increases were reported as an AE in 10% of patients. In the study, approximately 27% of patients died due to any AE, one of which (multi-organ failure) was considered by the investigator to be possibly related to study drug.
For more information, visit https://clinicaltrials.gov/ct2/show/NCT01611974.
Shire is planning to initiate two large randomized Phase 3 studies of maribavir for the treatment of CMV infection in transplant patients later this year. The first study SHP620-303 is a randomized study comparing maribavir to investigator’s choice anti-CMV treatment among transplant patients with resistant and/or refractory CMV disease.
The second study is a randomized double blind study SHP620-302 which will compare maribavir to oral valganciclovir among patients with hematopoietic stem cell transplant and asymptomatic CMV infection.
Maribavir, a member of a class of drugs called benzimidazole ribosides, is an orally bioavailable antiviral compound being investigated in patients with cytomegalovirus infection undergoing hematopoietic stem cell transplant or solid organ transplant who are resistant or refractory to drugs currently used to treat these infections. Maribavir is thought to inhibit viral DNA assembly and egress of viral capsids from the nucleus of infected cells. It has not been shown to affect the maturation of viral DNA or affect the viral DNA polymerase.
For further information please contact:
|+44 1256 894157
|+1 781 482 9018
|+44 1256 894874
|+1 781 482 2713
|+1 224 727 2079
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
- disruption from the acquisition and integration of Baxalta Incorporated (“Baxalta”) may make it more difficult to conduct business as usual or maintain relationships with patients, physicians, employees or suppliers;
- the company may not achieve some or all of the anticipated benefits of Baxalta’s spin-off from Baxter International, Inc. (“Baxter”) and the acquisition may have an adverse impact on Baxalta’s existing arrangements with Baxter, including those related to transition, manufacturing and supply services and tax matters;
- the failure to achieve the strategic objectives with respect to the acquisition of Baxalta may adversely affect the company’s financial condition and results of operations;
- products and product candidates may not achieve commercial success;
- product sales from ADDERALL XR and INTUNIV are subject to generic competition;
- the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for the company’s products may affect future revenues, financial condition and results of operations, particularly if there is pressure on pricing of products to treat rare diseases;
- supply chain or manufacturing disruptions may result in declines in revenue for affected products and commercial traction from competitors; regulatory actions associated with product approvals or changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
- the successful development of products in various stages of research and development is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
- the actions of certain customers could affect the company’s ability to sell or market products profitably, and fluctuations in buying or distribution patterns by such customers can adversely affect the company’s revenues, financial condition or results of operations;
- investigations or enforcement action by regulatory authorities or law enforcement agencies relating to the company’s activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters, tax audits and other disputes, including the company’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the company’s revenues, financial condition or results of operations;
- Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect the company’s ability to attract and/or retain the highly skilled personnel needed to meet its strategic objectives;
- failure to achieve the strategic objectives with respect to Shire’s acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. (“Dyax”) may adversely affect the company’s financial condition and results of operations;
- the company is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on the company’s revenues, financial condition or results of operations;
- the company may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners;
- difficulties in integrating Dyax or Baxalta into Shire may lead to the company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and
- other risks and uncertainties detailed from time to time in Shire’s, Dyax’s or Baxalta’s filings with the Securities and Exchange Commission, including those risks outlined in “ITEM 1A: Risk Factors” in Shire’s and Baxalta’s Annual Reports on Form 10-K for the year ended December 31, 2015.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.